| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ... Nature 515 (7528), 563-567, 2014 | 5652 | 2014 |
| TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ... Nature 554 (7693), 544-548, 2018 | 4333 | 2018 |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016 | 3925 | 2016 |
| Early childhood development coming of age: science through the life course MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ... The lancet 389 (10064), 77-90, 2017 | 3129 | 2017 |
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ... Nature 515 (7528), 558-562, 2014 | 2693 | 2014 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2274 | 2017 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1156 | 2018 |
| Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study DF McDermott, JA Sosman, M Sznol, C Massard, MS Gordon, O Hamid, ... Journal of Clinical Oncology 34 (8), 833-842, 2016 | 602 | 2016 |
| Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy FS Hodi, M Ballinger, B Lyons, JC Soria, M Nishino, J Tabernero, ... Journal of Clinical Oncology 36 (9), 850-858, 2018 | 348 | 2018 |
| A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. RS Herbst, MS Gordon, GD Fine, JA Sosman, JC Soria, O Hamid, ... Journal of Clinical Oncology 31 (15_suppl), 3000-3000, 2013 | 290 | 2013 |
| Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for atezolizumab B Vennapusa, B Baker, M Kowanetz, J Boone, I Menzl, JM Bruey, G Fine, ... Applied Immunohistochemistry & Molecular Morphology 27 (2), 92-100, 2019 | 177 | 2019 |
| A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies LH Sehn, SE Assouline, DA Stewart, J Mangel, RD Gascoyne, G Fine, ... Blood, The Journal of the American Society of Hematology 119 (22), 5118-5125, 2012 | 174 | 2012 |
| IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. WW Cruikshank, K Lim, AC Theodore, J Cook, G Fine, PF Weller, ... Journal of immunology (Baltimore, Md.: 1950) 157 (12), 5240-5248, 1996 | 159 | 1996 |
| Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). T Powles, NJ Vogelzang, GD Fine, JP Eder, FS Braiteh, Y Loriot, ... Journal of Clinical Oncology 32 (15_suppl), 5011-5011, 2014 | 135 | 2014 |
| Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). DR Spigel, SN Gettinger, L Horn, RS Herbst, L Gandhi, MS Gordon, ... Journal of Clinical Oncology 31 (15_suppl), 8008-8008, 2013 | 128 | 2013 |
| CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. AC Theodore, DM Center, J Nicoll, G Fine, H Kornfeld, WW Cruikshank Journal of immunology (Baltimore, Md.: 1950) 157 (5), 1958-1964, 1996 | 127 | 1996 |
| Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). DC Cho, JA Sosman, M Sznol, MS Gordon, A Hollebecque, O Hamid, ... Journal of Clinical Oncology 31 (15_suppl), 4505-4505, 2013 | 123 | 2013 |
| Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A … JC Soria, C Cruz, R Bahleda, JP Delord, L Horn, RS Herbst, D Spigel, ... European Journal of Cancer 49, S798-S798, 2013 | 121 | 2013 |
| Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients MV Mashikian, RE Tarpy, JJ Saukkonen, KG Lim, GD Fine, ... Journal of allergy and clinical immunology 101 (6), 786-792, 1998 | 89 | 1998 |
| A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). DF McDermott, MB Atkins, RJ Motzer, BI Rini, BJ Escudier, L Fong, ... Journal of Clinical Oncology 35 (6_suppl), 431-431, 2017 | 82 | 2017 |
